🔥 PCS-9: SBRT + ENZA Doubles Disease Control in Oligometastatic CRPC @OncoAlert @dr_cury . 🎯 Objective.• Evaluate whether adding SBRT to ADT + enzalutamide ⬆️ outcomes in oligometastatic CRPC (≤5 mets). 🏥 Methods.• Ph 2, randomized, 13 Canadian centers. • 100 men with

Join millions who have switched to Grok.

🔬 Can 20 Fractions Compete? Early Results from HYPOCx-iRex Trial. A phase II RCT exploring hypofractionation in LACC. Promising? Let’s dive in. 🎯 Objective.Evaluate safety & efficacy of 44 Gy/20F hypofractionated chemoradiation vs 45 Gy/25F. 🏥 Methods.• Open-label RCT (n=40)

🧠 Pre-Op FSRT vs Post-Op FSRT – New Data on Brain Met Resections! @OncoAlert . 🎯 Objective.Test if pre-op FSRT improves outcomes vs post-op FSRT in resected brain mets. 🏥 Methods.•458 pts / 534 mets.•27 Gy/3 fx or 30 Gy/5 fx.•LINAC/GK, 2–3 mm margins. 📊 Results

🎯 3-Year OS Nearly Doubled: ACCORD Trial Delivers! @OncoAlert . 🎯 Objective.Evaluate if adjuvant camrelizumab + capecitabine + ☢️ ⬆️ outcomes vs. observation after curative 🔪 for extrahepatic cholangiocarcinoma (EHC) & gallbladder cancer (GBC). 🏥 Methods.•Design: ACCORD RCT

🚨 New Evidence in High-Risk Thyroid Cancer: Can Radiotherapy Make the Difference?. 🎯 Objective.Evaluate outcomes & toxicity of adjuvant IMRT in high-risk differentiated thyroid cancer (DTC). 🏥 Methods.•Retrospective, single-center (2011–2024).•59 high-risk DTC pts (gross

🧠 ESTRON Trial: Can We Skip WBRT After Brain Met Resection? . 🎯 Objective.Compare hypofractionated stereotactic RT (HFSRT, 35 Gy/7fx) vs. whole-brain RT (WBRT, 30 Gy/10fx) post brain metastasis surgery, assessing control, toxicity & cognition. 🏥 Methods.Phase 2, randomized,

Summary key results !

🔥 RTOG 9601 – Long-Term Data Just Dropped! @OncoAlert . 📌 Salvage RT with vs. without Anti-Androgen Therapy (AAT) in men with post-prostatectomy recurrence (PSA 0.2–4.0, pT2/3N0).💊 24 months of bicalutamide 150 mg during & after RT. 🎯 18-Year Outcomes (n=760):.• 🧬 Overall

🚀 Could Radiation “Heat Up” Cold Tumors? New Evidence in NSCLC! @OncoAlert . 🎯 Objective.Evaluate whether ☢️ enhances immunotherapy efficacy in TMB-low, PDL1-null, or Wnt-mutated NSCLC. 🏥 Methods.• Design: Phase 2 RCT (NCT02492568).• Arms: Pembrolizumab ± SBRT (3x8Gy before

RT @FabArcidiacono8: You are in history. you are history! Great Jannik!.You are the CHAMPION🏆.The first Italian to win @Wimbledon🎾.The KIN….

🔥 Game-Changer in Salvage RT: PSA-Guided Hormone Therapy.@OncoAlert .🎯 Objective:.•Determine survival benefit of adding ADT to postoperative RT based on pre-RT PSA levels.🏥 Methods:.•Meta-analysis of RCTs (n = 5 trials; RT ± ADT).•Short-course ADT (4–6 mo) vs long-course

🚨BREAKING: RAVENS Trial Redefines Oligometastatic Prostate Care! 🚨@OncoAlert .🎯 Objective:.• Assess if Ra223+ SABR) delays progression in bone omCSPC by targeting subclinical disease.🏥 Methods:.• RCT w/ 64 👥 (1:1 randomization).• Eligibility: ≤3 bone metastases

RT @CJTsaiMDPhD: @FabArcidiacono8 @jryckman3 @PaolaAnselmo7 @gusviani Can't wait to see the results!.